N/A
N=527
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
Cataract
Bottom Line
View on ClinicalTrials.gov: NCT04290676 ↗Enrolled (actual)
527
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Percentage of Eyes With Anterior Chamber Cell Grade 0 — 65 percentage of eyes
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- DEXYCU (dexamethasone intraocular suspension) 9%. (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- EyePoint Pharmaceuticals, Inc.
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Eyes With Anterior Chamber Cell Grade 0 |
65 | — |
Summary
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Eligibility Criteria
Inclusion Criteria
- Male and Female subjects at least 18 years of age
- Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU
Exclusion Criteria
- Subjects who underwent cataract surgery and did not receive DEXYCU
Data sourced from ClinicalTrials.gov (NCT04290676). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.